Biologic · anti-IgEInternational pack · 150 mg shown
Omalizumab
75 / 150 / 300 mg presentations
Subcutaneous
Targeted therapies.
Find targeted options
Treatment indications
Match
Select an indication to start.
Clinical basis & limits
This shortlist screens the listed Canadian indications. Unanswered criteria remain to be confirmed. Review the product’s dosing, contraindications, monitoring and coverage separately.
Trial thresholds and payer rules are not automatically used as approval requirements. Canadian monographs are linked in each result; age and weight requirements depend on the indication.
Biologic · anti-IgERepresentative presentation
Omalizumab
75 / 150 mg prefilled presentations
Subcutaneous
Oral · leukotriene receptorUS reference · Singulair 10 mg
Montelukast sodium · Singulair / generics
Asthma 2+ yearsSeasonal rhinitis 15+ years
Once daily · evening
- 10 mgFilm-coated tablet15+ years
- 5 mgChewable tablet6–14 years
- 4 mgChewable tablet2–5 years
Biologic · IL-4 / IL-13US reference · 200 & 300 mg
Dupilumab
200 mg / 1.14 mL · 300 mg / 2 mL
Subcutaneous
Biologic · anti-IL-5International device · 100 mg shown
Mepolizumab
100 mg · 40 mg paediatric syringe
Subcutaneous
Biologic · anti-IL-5Representative US syringe
Depemokimab
100 mg / 1 mL
Subcutaneous
Biologic · IL-5 receptorUS pack & pen
Benralizumab
30 mg / 1 mL
Subcutaneous
Biologic · anti-IL-5US vial
Reslizumab
10 mg/mL · 100 mg vial
Intravenous infusion18+ years · eos ≥400/µL at initiation
Biologic · anti-TSLPUS pack & pen
Tezepelumab
210 mg / 1.91 mL
Subcutaneous
Biologic · anti-IL-13Representative · UK syringe pack
Tralokinumab
150 mg syringe · 300 mg pen
Subcutaneous12+ years
Biologic · anti-IL-13International device
Lebrikizumab
250 mg / 2 mL
Subcutaneous12+ years · ≥40 kg
Biologic · IL-31 receptorInternational device
Nemolizumab
30 mg dual-chamber pen
Subcutaneous
Oral · BTK inhibitorUS pack
Remibrutinib
25 mg tablet
25 mg orally twice daily
Oral18+ years
Oral · JAK inhibitorUS pack · 15 mg shown
Upadacitinib
15 / 30 mg extended-release tablets · AD
Oral12+ years · adolescents ≥40 kgOnce daily
Oral · JAK inhibitorUS pack · 100 mg shown
Abrocitinib
50 / 100 / 200 mg tablets
Oral12+ yearsOnce daily